Search results
Results from the WOW.Com Content Network
Triazolam is short-acting, is lipophilic, and is metabolized hepatically via oxidative pathways. Triazolam produces one short-acting active metabolite, alpha-hydroxytriazolam, which is suspected to be of minor clinical significance. [31] The half-life of triazolam is only 2 hours making it a very short acting benzodiazepine drug. [32]
Triazolam: Halcion, Rilamir, Notison, Somese: 1980 0.125, 0.25 0.5: 0.5–2: 2: hypnotic: Drug Name Common Trade Names Year Approved Typical Dosages of Oral Tablets (mg) Approx. Equivalent Oral Dose to 10mg Diazepam (mg) Peak onset of action (hours) Elimination Half-life of Active Metabolite (hours) Primary Therapeutic Use
Halcion (Triazolam) is most well known for the treatment of insomnia. It is highly effective when used in oral sedation protocols, and if deemed appropriate by your dentist, can be used in conjunction with an antihistamine. Sonata (Zaleplon) is similar to Halcion in that it is also commonly used for the treatment of insomnia.
Both substance use and alcohol can cause both long-term and short-term memory loss, resulting in blackouts. The most commonly used group of prescription drugs which can produce amnesia are benzodiazepines, especially if combined with alcohol, however, in limited quantities, triazolam (Halcion) is not associated with amnesia or memory impairment ...
Dahmer was prescribed Halcion, a sedative that contains the drug triazolam, by a physician to help with his sleeping issues, according to a study by The New School Psychology Bulletin. At the time ...
Non-medical benzodiazepine use is mostly limited to individuals who use other substances, i.e., people who engage in polysubstance use. [223] On the international scene, benzodiazepines are categorized as Schedule IV controlled drugs by the INCB , apart from flunitrazepam , which is a Schedule III drug under the Convention on Psychotropic ...
Temazepam and similar hypnotics, such as triazolam (Halcion) are generally reserved for severe and debilitating insomnia. They have largely been replaced by z-drugs ( zopiclone , zolpidem ) and atypical antidepressants ( trazodone , mirtazapine ) as first line treatment for insomnia.
There could be new hope on for kidney cancer patients. Researchers announced early results of an anti-tumor vaccine for patients with stage 3 or 4 kidney cancer, who face high recurrence risk.